
The regulatory burden of new clinical trials has slowed progress.
Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments

Comments